Find recruiting clinical trials for sarcoma (soft tissue and bone) in the UK — including subtype-specific targeted therapies, NY-ESO-1 T-cell receptor therapy, trabectedin and pazopanib combinations, and the UK sarcoma reference centre network. See your treatment pathway and where trials fit in.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Tumour confined to the limb or trunk wall
Standard: Wide local excision, radiotherapy (pre- or post-operative), doxorubicin + ifosfamide for high-risk
Osteosarcoma, Ewing sarcoma, chondrosarcoma — primary bone tumours
Standard: Neoadjuvant chemotherapy (MAP for osteosarcoma, VIDE for Ewing), limb-salvage surgery, adjuvant chemotherapy
Inoperable or metastatic soft tissue sarcoma
Standard: Doxorubicin first-line, trabectedin (leiomyosarcoma, liposarcoma), pazopanib, eribulin, gemcitabine + docetaxel
Gastrointestinal stromal tumour and other specific sarcoma subtypes
Standard: Imatinib, sunitinib, regorafenib, ripretinib (GIST); subtype-specific protocols for others
CDK4/6 inhibitors in well-differentiated liposarcoma, MDM2 antagonists, NTRK inhibitors for TRK-fusion sarcomas, and PARP inhibitors in Ewing sarcoma are all being tested in subtype-enriched trials.
Genetically engineered T-cell receptor therapy targeting the NY-ESO-1 antigen — highly expressed in synovial sarcoma and myxoid liposarcoma. UK centres at UCLH and the Royal Marsden are recruiting for these trials.
Checkpoint inhibitors alone have limited efficacy in sarcomas, but combinations with pazopanib (vascular disruption), trabectedin (immunogenic cell death), and doxorubicin are being explored in UK sarcoma trials.
Sarcomas disproportionately affect children, adolescents, and young adults. Several UK paediatric oncology trials (via CCLG) focus on osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma with novel agents.
Loading trials from ClinicalTrials.gov...
Yes. Many sarcoma trials recruit patients with recurrent or metastatic disease after standard chemotherapy. Adjuvant trials also recruit after surgery to reduce the chance of recurrence.
Yes. Several UK trials focus on specific subtypes — including GIST (imatinib resistance), synovial sarcoma (NY-ESO-1 targeted therapies), liposarcoma (CDK4 inhibitors), and Ewing sarcoma (PARP inhibitors).
Checkpoint inhibitors alone have limited activity in most sarcomas, but trials are testing combinations with pazopanib and trabectedin. T-cell receptor therapy targeting NY-ESO-1 is showing promise in synovial sarcoma.
Yes. All sarcoma trials in the UK run through NHS sarcoma reference centres or the London Sarcoma Service at UCLH and the Royal Marsden. Your GP or oncologist can refer you.
Use our search above to find trials matching your condition and location. Review eligibility criteria carefully.
Talk to your GP or oncologist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.